Riskpilot← Back to searchSign inGet full accessNEVRO ARENDAL AS
ASActiveOrg 919909978Stoaveien 9, 4848 ArendalGeneral medical practice activities · NACE 8621Est. 20174 employees
Revenue 2024
NOK 11M
+6% vs 2023
EBITDA margin
72.7%
+21% vs 2023
Equity ratio
27.6%
Financial strength
Net profit 2024
NOK 6,1M
+21% vs 2023
| Revenue | NOK 11M | +6% |
| EBITDA | NOK 8M | +21% |
| Net profit | NOK 6,1M | +21% |
| Total assets | NOK 8,8M | +15% |
| Equity | NOK 2,4M | +554% |
| Employees | 4 | — |
Legal name
NEVRO ARENDAL AS
Org number
919909978
Legal form
Aksjeselskap
NACE code
8621 · General medical practice activities
Founded
15. november 2017
Share capital
NOK 30 000
Employees
4 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Levere helsetjenester innen nevrologi med dertil hørende virksomhet, samt investering og deltakelse i annen virksomhet.
Address
Stoaveien 9, 4848 Arendal
Phone
+4737095200
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 7 724 | 8 491 | 9 077 | 10 305 | 10 964 |
| Staff expenses | −1 416 | −1 580 | −2 330 | −2 605 | −1 957 |
| EBITDA | 5 619 | 5 922 | 5 719 | 6 583 | 7 968 |
| Depreciation & amort. | −69 | −207 | −160 | −160 | −186 |
| EBIT | 5 550 | 5 715 | 5 559 | 6 423 | 7 781 |
| Net financials | −1 | −0 | −1 | 0 | −15 |
| Profit before tax | 5 549 | 5 715 | 5 559 | 6 423 | 7 766 |
| Tax | 1 221 | 1 257 | 1 234 | −0 | 1 712 |
| Net profit | 4 328 | 4 458 | 4 324 | 5 010 | 6 054 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 5 946 | 6 258 | 6 348 | 7 611 | 8 776 |
| Equity | 109 | 566 | 361 | 371 | 2 425 |
| Long-term debt | 34 | 39 | 29 | 21 | 52 |
| Short-term debt | 5 804 | 5 653 | 5 958 | 7 219 | 6 299 |
| Total debt | 5 838 | 5 692 | 5 987 | 7 240 | 6 351 |
EBITDA margin
72.7%
This company
15.8%
Market median
+360% vs market
20202024
Equity ratio
27.6%
This company
38.2%
Market median
-28% vs market
20202024
Return on equity
249.7%
This company
18.4%
Market median
+1257% vs market
20202024
Net profit margin
55.2%
This company
8.1%
Market median
+581% vs market
20202024
Asset turnover
1.25×
This company
1.12×
Market median
+12% vs market
20202024
Debt / equity
2.62×
This company
0.62×
Market median
-323% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HH Deputy Member | Deputy Member | 2017 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2017 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NEVRO ARENDAL AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Haugen | Deputy Member | 0 companies |
| Karen Herlofson | Chairman | 0 companies |